Worth reading
50Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-4.2
% (year-on-year change in interim net income attributable to owners of the parent)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPNet Sales64,688¥ millionYear on year -0.2%Progress 45.6%
Operating profit10,563¥ millionYear on year -0.9%Progress 41.4%
Ordinary income10,974¥ millionYear on year +0.4%Progress 43.0%
Net income attributable to owners of the parent7,263¥ millionYear on year -4.2%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥268.69
Financial position at period-end
Total assets231,532¥ million
of which net assets 196,374 ¥ millionEquity ratio 84.8%vs. prior year-end +1.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenuePhysiological measuring equipment ¥10,416 million (YoY -5.9%), Patient Monitoring Systems ¥3,475 million (YoY -0.6%), Treatment equipment ¥31,819 million (YoY +1.5%), Consumables and other products ¥18,977 million (YoY +0.4%)
Segment profitPhysiological measuring equipment ¥1,519 million, Patient Monitoring Systems ¥564 million, Treatment equipment ¥5,733 million, Consumables and other products ¥2,746 million
Regional sales¥63,685 million, ¥1,003 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥142,000 million (YoY +1.6%)
Operating profit¥25,500 million (YoY -4.2%)
Ordinary income¥25,500 million (YoY -6.7%)
Profit attributable to owners of the parent¥17,700 million (YoY -5.8%)
Annual Dividend Forecast¥230 → ¥230（0.0%）
Factors Behind Changes in Business Performance
Lower revenue from automated hematology analyzers and ECG-related products; lower revenue from patient monitors; growth in the home healthcare rental business; and higher revenue from consumables and other products.
Disclosure regarding the going concern assumption
None
Change in accounting policy
基準改正に伴う変更 Noneそれ以外の変更 None見積りの変更 None修正再表示 None
Material subsequent eventsAt a Board of Directors meeting held on 30 October 2026, the company resolved to hold an extraordinary general meeting of shareholders on 24 December 2026 and submit a proposal for the election of 1 audit & supervisory board member.
Impairment loss¥11 million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥2 million, Gain on sale of investment securities ¥78 million, Insurance surrender value ¥19 million / Extraordinary loss Loss on sale of property, plant and equipment ¥1 million, Impairment loss ¥11 million, Impairment Losses on Investment Securities ¥49 million, Building demolition costs ¥1 million, Business restructuring loss ¥184 million
Availability of Supplementary Financial Results MaterialsNone
Availability of Financial Results BriefingWhether applicable None / Subject person Not disclosed
Issued Shares at Period-End37,747,300 Shares
Treasury Shares at Period-End10,678,419 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥64,688 million (YoY -0.2%) |
| Operating profit | ¥10,563 million (YoY -0.9%) |
| Ordinary income | ¥10,974 million (YoY +0.4%) |
| Profit attributable to owners of the parent | ¥7,263 million (YoY -4.2%) |
| Net income per share | ¥268.69 |
| Equity ratio | End of the current fiscal period 84.8 / End of previous period 83.8 |
| Total assets | ¥231,532 million |
| Net assets | ¥196,374 million |
| Full-year earnings forecast | Net Sales ¥142,000 million (YoY +1.6%) / Operating profit ¥25,500 million (YoY -4.2%) / Ordinary income ¥25,500 million (YoY -6.7%) / Profit attributable to owners of the parent ¥17,700 million (YoY -5.8%) |
| Annual Dividend Forecast | ¥230 → ¥230（0.0%） |
| Segment revenue | Physiological measuring equipment ¥10,416 million (YoY -5.9%), Patient Monitoring Systems ¥3,475 million (YoY -0.6%), Treatment equipment ¥31,819 million (YoY +1.5%), Consumables and other products ¥18,977 million (YoY +0.4%) |
| Segment profit | Physiological measuring equipment ¥1,519 million, Patient Monitoring Systems ¥564 million, Treatment equipment ¥5,733 million, Consumables and other products ¥2,746 million |
| Regional sales | ¥63,685 million, ¥1,003 million |
| Impairment loss | ¥11 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥2 million, Gain on sale of investment securities ¥78 million, Insurance surrender value ¥19 million / Extraordinary loss Loss on sale of property, plant and equipment ¥1 million, Impairment loss ¥11 million, Impairment Losses on Investment Securities ¥49 million, Building demolition costs ¥1 million, Business restructuring loss ¥184 million |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Material subsequent events | At a Board of Directors meeting held on 30 October 2026, the company resolved to hold an extraordinary general meeting of shareholders on 24 December 2026 and submit a proposal for the election of 1 audit & supervisory board member. |
| Availability of Supplementary Financial Results Materials | None |
| Availability of Financial Results Briefing | Whether applicable None / Subject person Not disclosed |
| Issued Shares at Period-End | 37,747,300 Shares |
| Treasury Shares at Period-End | 10,678,419 Shares |
| Factors Behind Changes in Business Performance | Lower revenue from automated hematology analyzers and ECG-related products; lower revenue from patient monitors; growth in the home healthcare rental business; and higher revenue from consumables and other products. |
Items this document does not state (11)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyOrders received and order backlogDepreciation and amortizationChanges in the scope of consolidation
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from automated hematology analyzers, ECG-related products and monitors declined, while revenue from the home healthcare rental business and consumables and other products increased. The company also explained that uncertainty continues due to U.S. trade policy and geopolitical risks, particularly in Europe and the Middle East.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.